Zomedica Accounts Payable vs Total Current Liabilities Analysis

ZOM Stock

USD 0.17 0.01 5.56%

Zomedica Pharmaceuticals financial indicator trend analysis is more than just analyzing Zomedica Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zomedica Pharmaceuticals is a good investment. Please check the relationship between Zomedica Pharmaceuticals Accounts Payable and its Total Current Liabilities accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

Accounts Payable vs Total Current Liabilities

Accounts Payable vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zomedica Pharmaceuticals Accounts Payable account and Total Current Liabilities. At this time, the significance of the direction appears to have totally related.

The correlation between Zomedica Pharmaceuticals' Accounts Payable and Total Current Liabilities is 1.0. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Zomedica Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Zomedica Pharmaceuticals' Accounts Payable and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Zomedica Pharmaceuticals Corp are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Accounts Payable i.e., Zomedica Pharmaceuticals' Accounts Payable and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Zomedica Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Zomedica Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Current Liabilities

Total Current Liabilities is an item on Zomedica Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Zomedica Pharmaceuticals Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Zomedica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

At this time, Zomedica Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 21st of May 2024, Sales General And Administrative To Revenue is likely to grow to 1.30, while Issuance Of Capital Stock is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.5M	6.7M	6.3M	6.6M
Interest Income	321.1K	2.5M	5.6M	5.9M

Depreciation And Amortization Interest Income

Zomedica Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Long Term Debt	Short Term Debt	Intangible Assets
Total Assets		-0.09	0.92	1.0	-0.55	-0.95	0.56	0.95	0.39	0.2	0.93	0.76	0.84	0.94	0.91	0.99	0.77	-0.13	0.99	0.76	0.89	0.51	0.77	0.82	0.84	0.95
Other Current Liab	-0.09		0.0	-0.1	-0.13	-0.01	0.13	-0.16	0.54	0.92	0.0	0.02	0.15	0.0	-0.15	-0.03	0.27	0.17	-0.09	-0.15	0.0	0.25	-0.18	-0.06	0.02	-0.17
Total Current Liabilities	0.92	0.0		0.91	-0.23	-0.97	0.25	0.97	0.37	0.33	0.73	0.88	0.84	0.76	0.98	0.94	0.8	-0.11	0.91	0.91	1.0	0.42	0.92	0.83	0.88	0.96
Total Stockholder Equity	1.0	-0.1	0.91		-0.55	-0.94	0.56	0.95	0.38	0.18	0.93	0.76	0.83	0.94	0.91	0.99	0.77	-0.13	0.99	0.75	0.89	0.49	0.76	0.81	0.83	0.95
Net Debt	-0.55	-0.13	-0.23	-0.55		0.41	-1.0	-0.25	-0.21	-0.14	-0.81	-0.05	-0.45	-0.79	-0.16	-0.52	-0.32	0.08	-0.55	0.01	-0.17	-0.53	0.0	-0.45	-0.32	-0.31
Retained Earnings	-0.95	-0.01	-0.97	-0.94	0.41		-0.42	-0.94	-0.34	-0.32	-0.83	-0.81	-0.91	-0.85	-0.93	-0.97	-0.79	0.12	-0.95	-0.86	-0.96	-0.56	-0.86	-0.91	-0.91	-0.94
Cash	0.56	0.13	0.25	0.56	-1.0	-0.42		0.26	0.21	0.14	0.82	0.06	0.46	0.8	0.17	0.53	0.33	-0.08	0.56	0.01	0.19	0.54	0.01	0.47	0.34	0.32
Non Current Assets Total	0.95	-0.16	0.97	0.95	-0.25	-0.94	0.26		0.36	0.16	0.76	0.86	0.79	0.78	0.99	0.95	0.76	-0.12	0.94	0.88	0.97	0.36	0.89	0.76	0.84	0.99
Non Currrent Assets Other	0.39	0.54	0.37	0.38	-0.21	-0.34	0.21	0.36		0.68	0.36	0.43	0.45	0.37	0.37	0.4	0.25	0.09	0.44	0.36	0.35	0.38	0.34	0.05	0.47	0.38
Other Assets	0.2	0.92	0.33	0.18	-0.14	-0.32	0.14	0.16	0.68		0.21	0.34	0.45	0.21	0.18	0.27	0.45	0.13	0.21	0.19	0.32	0.43	0.16	0.21	0.36	0.15
Cash And Short Term Investments	0.93	0.0	0.73	0.93	-0.81	-0.83	0.82	0.76	0.36	0.21		0.54	0.79	1.0	0.69	0.91	0.68	-0.13	0.92	0.51	0.69	0.61	0.52	0.77	0.73	0.78
Other Stockholder Equity	0.76	0.02	0.88	0.76	-0.05	-0.81	0.06	0.86	0.43	0.34	0.54		0.66	0.57	0.88	0.79	0.66	0.29	0.76	0.85	0.88	0.23	0.86	0.6	0.73	0.85
Total Liab	0.84	0.15	0.84	0.83	-0.45	-0.91	0.46	0.79	0.45	0.45	0.79	0.66		0.8	0.79	0.89	0.68	-0.15	0.85	0.72	0.81	0.84	0.7	0.89	0.97	0.78
Total Current Assets	0.94	0.0	0.76	0.94	-0.79	-0.85	0.8	0.78	0.37	0.21	1.0	0.57	0.8		0.72	0.93	0.7	-0.13	0.94	0.54	0.71	0.61	0.55	0.78	0.75	0.81
Net Receivables	0.91	-0.15	0.98	0.91	-0.16	-0.93	0.17	0.99	0.37	0.18	0.69	0.88	0.79	0.72		0.92	0.71	-0.12	0.91	0.94	0.98	0.36	0.94	0.76	0.87	0.98
Common Stock Shares Outstanding	0.99	-0.03	0.94	0.99	-0.52	-0.97	0.53	0.95	0.4	0.27	0.91	0.79	0.89	0.93	0.92		0.78	-0.11	0.99	0.79	0.92	0.55	0.8	0.86	0.88	0.95
Other Current Assets	0.77	0.27	0.8	0.77	-0.32	-0.79	0.33	0.76	0.25	0.45	0.68	0.66	0.68	0.7	0.71	0.78		-0.01	0.71	0.5	0.8	0.37	0.51	0.68	0.59	0.69
Common Stock	-0.13	0.17	-0.11	-0.13	0.08	0.12	-0.08	-0.12	0.09	0.13	-0.13	0.29	-0.15	-0.13	-0.12	-0.11	-0.01		-0.13	-0.11	-0.11	-0.14	-0.11	-0.19	-0.15	-0.13
Net Tangible Assets	0.99	-0.09	0.91	0.99	-0.55	-0.95	0.56	0.94	0.44	0.21	0.92	0.76	0.85	0.94	0.91	0.99	0.71	-0.13		0.79	0.88	0.52	0.8	0.8	0.86	0.96
Property Plant And Equipment Net	0.76	-0.15	0.91	0.75	0.01	-0.86	0.01	0.88	0.36	0.19	0.51	0.85	0.72	0.54	0.94	0.79	0.5	-0.11	0.79		0.91	0.29	1.0	0.7	0.84	0.91
Accounts Payable	0.89	0.0	1.0	0.89	-0.17	-0.96	0.19	0.97	0.35	0.32	0.69	0.88	0.81	0.71	0.98	0.92	0.8	-0.11	0.88	0.91		0.36	0.92	0.8	0.85	0.95
Non Current Liabilities Total	0.51	0.25	0.42	0.49	-0.53	-0.56	0.54	0.36	0.38	0.43	0.61	0.23	0.84	0.61	0.36	0.55	0.37	-0.14	0.52	0.29	0.36		0.25	0.68	0.76	0.35
Property Plant And Equipment Gross	0.77	-0.18	0.92	0.76	0.0	-0.86	0.01	0.89	0.34	0.16	0.52	0.86	0.7	0.55	0.94	0.8	0.51	-0.11	0.8	1.0	0.92	0.25		0.69	0.81	0.92
Short Long Term Debt	0.82	-0.06	0.83	0.81	-0.45	-0.91	0.47	0.76	0.05	0.21	0.77	0.6	0.89	0.78	0.76	0.86	0.68	-0.19	0.8	0.7	0.8	0.68	0.69		0.86	0.77
Short Term Debt	0.84	0.02	0.88	0.83	-0.32	-0.91	0.34	0.84	0.47	0.36	0.73	0.73	0.97	0.75	0.87	0.88	0.59	-0.15	0.86	0.84	0.85	0.76	0.81	0.86		0.85
Intangible Assets	0.95	-0.17	0.96	0.95	-0.31	-0.94	0.32	0.99	0.38	0.15	0.78	0.85	0.78	0.81	0.98	0.95	0.69	-0.13	0.96	0.91	0.95	0.35	0.92	0.77	0.85

Click cells to compare fundamentals

Zomedica Pharmaceuticals Account Relationship Matchups

Zomedica Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.2M	66.1M	280.4M	279.6M	253.2M	265.9M
Other Current Liab	1.0	1.2M	501.5K	265K	172K	163.4K
Total Current Liabilities	2.1M	2.0M	4.3M	7.8M	9.0M	9.5M
Total Stockholder Equity	2.1M	51.1M	270.9M	267.4M	240.0M	252.0M
Net Debt	(510.6K)	(60.1M)	(193.6M)	(25.7M)	(10.2M)	(10.7M)
Retained Earnings	(52.1M)	(69.0M)	(119.4M)	(136.4M)	(170.9M)	(162.4M)
Cash	510.6K	62.0M	195.0M	27.4M	13.0M	12.3M
Non Current Assets Total	2.4M	3.3M	80.0M	156.1M	153.3M	161.0M
Non Currrent Assets Other	(2.4M)	1M	659.1K	453K	1.1M	1.1M
Cash And Short Term Investments	510.6K	62.0M	195.0M	115.1M	90.5M	95.0M
Liabilities And Stockholders Equity	4.2M	66.1M	280.4M	279.6M	253.2M	265.9M
Other Stockholder Equity	3.6M	2.8M	9.3M	23.7M	29.9M	31.4M
Total Liab	2.1M	15.1M	9.5M	12.2M	13.2M	13.8M
Total Current Assets	1.8M	62.9M	200.4M	123.5M	99.9M	104.9M
Net Receivables	67.6K	146.2K	765.5K	1.9M	2.2M	2.3M
Common Stock Shares Outstanding	106.3M	364.4M	956.5M	979.9M	979.9M	1.0B
Other Current Assets	1.2M	727.8K	1.8M	3.8M	2.1M	1.4M
Accumulated Other Comprehensive Income	0.0	459.6K	1.7K	(843K)	48K	59.2K
Common Stock	38.6M	104.8M	381.0M	381.0M	342.9M	325.7M
Net Tangible Assets	(10.4M)	50.7M	194.1M	161.6M	185.9M	195.1M
Property Plant And Equipment Net	1.8M	1.9M	2.5M	9.2M	25.3M	26.6M
Accounts Payable	2.1M	1.2M	3.2M	6.7M	7.7M	8.1M
Common Stock Total Equity	38.6M	459.6	381.0M	381.0M	438.1M	460.0M
Retained Earnings Total Equity	(52.1M)	(69.0M)	(119.4M)	(136.4M)	(122.8M)	(116.6M)
Short Term Investments	570.0K	1.3M	1.0M	87.7M	77.5M	81.4M
Property Plant And Equipment Gross	2.4M	583.01	3.4M	10.4M	27.3M	28.7M
Intangible Assets	543.4K	376.6K	33.5M	41.8M	55.4M	58.1M
Property Plant Equipment	1.8M	583.0K	2.5M	6.8M	7.8M	8.2M
Cash And Equivalents	510.6K	62.0M	195.0M	27.4M	31.5M	46.1M
Capital Surpluse	3.6M	14.8M	9.3M	23.7M	27.2M	28.6M
Net Invested Capital	(9.9M)	51.6M	270.9M	267.4M	240.0M	130.1M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Zomedica Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:

How To Invest In Zomedica

Details

Is Zomedica Stock a good investment?

Details

What is Zomedica Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Zomedica Stock analysis

When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios

Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.04)

Revenue Per Share

0.026

Quarterly Revenue Growth

0.142

Return On Assets

(0.08)

Return On Equity

(0.15)

The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zomedica Accounts Payable vs Total Current Liabilities Analysis

Accounts Payable vs Total Current Liabilities

Accounts Payable vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Accounts Payable

Total Current Liabilities

Zomedica Pharmaceuticals fundamental ratios Correlations

Zomedica Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zomedica Pharmaceuticals fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Zomedica Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock Shares Outstanding	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Accounts Payable	- 0.96	Retained Earnings
Net Tangible Assets	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Total Assets